Latest Headlines Top Stories Breaking News Stock Alerts Wallstreet Events Industry News Industry News Corp.
Calendars Stock Splits Conference Calls Earnings Calendar Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings FDA Calendars Drug Approvals Clinical Trial Calendar Ratings Changes Cov Initiations Cov.
Reiterated Economic News Economic Calendar Economic Scorecard Cryptocurrency Cryptocurrency Morning Mkt Analysis US Commentary European Commentary Asian Commentary Canadian Commentary Indian Commentary Commodities White House General News FX Top Stories Currency Analysis Currency Alerts Economic Calendar Economic Scorecard Coronavirus COVID-19 Calendar Diet & Fitness Kids Health Men's Health Women's Health Cancer News Drug Development Mental Health Slide Shows Entertainment Entertainment Top Stories Classic Rock Rap/Hip-Hop Alternative Content Licensing Content Licensing Newswires & Feeds Content Syndication Digital Signage Services Radio News Services Premium Services Intelligent Investor Biotech Investor NEW Latest News Videos Free Content Press Releases Latest Headlines Stock Alerts Top Stories Breaking News Wallstreet Events Industry News Corp.
Calendars Stock Splits Conference Calls Earnings Calendar Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings FDA Calendars Drug Approvals Clinical Trial Calendar Ratings Changes Cov Initiations Cov.
Reiterated Economic Calendar Economic Scorecard Cryptocurrency Market News Morning Mkt Analysis US Commentary European Commentary Asian Commentary Canadian Commentary Indian Commentary Commodities White House General News FX Top Stories Currency Analysis Currency Alerts Economic Calendar Economic Scorecard Health News Coronavirus COVID-19 Calendar Diet & Fitness Kids Health Men's Health Women's Health Cancer News Drug Development Mental Health Slide Shows Entertainment Entertainment News Top Stories Classic Rock Rap/Hip-Hop Alternative Content Licensing Newswires & Feeds Content Syndication Digital Signage Services Radio News Services Intelligent Investor Biotech Investor Latest News Videos Free Content Press Releases Biotech Daily Dose Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up By TajSabreen Ahamed ✉ | Published: 6/17/2026 11:53 PM ET Addas your preferred news source on Google GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the U.S.
FDA has approved Utebzi (tebipenem pivoxil) as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, including pyelonephritisi, caused by certain susceptible pathogens in patients with limited or no alternative oral treatment options.
The decision follows a previous FDA Complete Response Letter (CRL) issued in June 2022, when the agency determined that additional data were needed to support the approval while the program was still under Spero Therapeutics' ownership.
After GSK entered into an exclusive licensing agreement with Spero later that year, the companies resubmitted the NDA in December 2025, supported by new evidence from the successful Phase 3 PIVOT-PO trial.
The PIVOT-PO study demonstrated that Utebzi was non-inferior to intravenous therapy, meeting the primary efficacy endpoint in adults with cUTIs.
The company said the oral formulation may help reduce reliance on hospital-based IV antibiotics, ease patient burden, and support outpatient management as antimicrobial resistance continues to rise.
More than 3 million cUTI cases occur annually in the U.S., with treatment failure affecting up to 34% of patients, often due to multidrug-resistant infections.
These infections contribute to over $6 billion in healthcare costs each year, and reliance on IV carbapenems has historically increased hospital burden and reduced patient quality of life.
Utebzi provides a potential outpatient alternative that may reduce dependence on hospital-based IV therapy.
Tony Wood, CSO at GSK, said the approval comes at a critical time as antibiotic resistance continues to rise, noting that an effective oral carbapenem "could help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections." Dr.
Bilal Chughtai, Chief of Urology at Plainview Hospital, Northwell Health, called the approval a "major milestone," for patients who previously had few oral treatment alternatives.
SPRO has traded between $1.80 and $3.22 over the past year.
The stock closed Wednesday's trading at $2.36, down 14.62%.
During overnight trading the stock is at $2.65, up 25.59%.
For comments and feedback contact: editorial@rttnews.com Business News Slide Shows Biotech Stocks Facing FDA Decision In June 2026 Biotech Stocks Facing FDA Decision In May 2026 Biotech Stocks Facing FDA Decision In April 2026 Latest Updates on Middle East War U.S.
Dollar Advances Amid Concerns Of Delay In Oil Output Recovery In Gulf June 17,....
